INTRODUCTION INTRODUCTION
• Management of moderate psoriasis remains a signifi cant challenge, with some evidence suggesting patients with moderate disease are often undertreated and experience unsatisfactory clinical outcomes. 1, 2 However, there is a lack of consensus on how to defi ne moderate psoriasis, and no explicit guidelines exist for the treatment of this patient population.
• Apremilast (APR), an oral phosphodiesterase 4 inhibitor, is the fi rst new oral systemic, nonbiologic medication approved for the treatment of psoriasis in the past 20 years, and is approved in the United States for treatment of adult patients with active psoriatic arthritis (PsA) and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 3 • Given the lack of guidance for treating patients with moderate psoriasis and the recent availability of APR, the objectives of the current investigation were (1) to determine how dermatologists in the real-world clinical setting defi ne and treat moderate plaque psoriasis, and (2) to describe real-world clinical characteristics and 6-month treatment outcomes among patients with moderate psoriasis treated with APR.
METHODS METHODS

Dermatologist Survey
• The survey portion of the investigation was conducted between October 2015 and July 2016.
• US dermatologists treating patients with psoriasis were invited to complete an online survey which asked: -How they typically assess psoriasis severity -What cutoff criteria they use to defi ne moderate psoriasis -Which treatments they commonly prescribe to patients with moderate plaque psoriasis
• Eligible survey participants were US dermatologists who: -Treat ≥20 adult patients with plaque psoriasis per month, ≥1% of whom must be considered to have moderate psoriasis -Spend ≥40% of practice time in medical dermatology or ≥70% in medical and surgical dermatology -Have been in practice for 2 to 30 years -Spend >75% of practice time in direct patient care
Prospective 6-Month Patient Chart Review
• Surveyed dermatologists were also asked to provide data from charts of 4 patients with a diagnosis of moderate plaque psoriasis whom they had seen in the last month, including ≥1 patient treated with APR; 6 months later they were invited to provide follow-up patient chart information.
• The patients were required to meet the following criteria: 
RESULTS RESULTS
Dermatologist Survey
Respondent Dermatologists • A total of 150 dermatologists responded to the survey.
• Dermatologists had an average of 13.5 years in practice; most currently worked in a single-physician or multiphysician dermatology specialty practice (83%). They saw an average of 72 patients with psoriasis per month.
Scales Used to Assess Psoriasis Severity
• The large majority of dermatologists (95%) reported they assessed disease severity based on the percentage of psoriasis-affected body surface area (BSA) ( Figure 1 ).
-59% of dermatologists responded that they also considered location of the affected area in their assessment of severity. 
Figure 1. Criteria Used to Assess Psoriasis Severity
Treatment of Moderate Plaque Psoriasis
• When asked to estimate what proportions of their patients with moderate plaque psoriasis receive various types of medications as their primary treatment, dermatologists reported that 47% were receiving biologic agents, 28% prescription topicals, 18% oral systemics, 5% phototherapy, and 2% over-the-counter (OTC) topical agents ( Figure 3 ). 
RESULTS (cont'd) RESULTS (cont'd)
• At the 6-month chart review, among patients treated with APR at baseline, 91% (64/70) remained on APR; 3 patients were new to APR (Figure 4 ).
• 65 patients (24%) were receiving APR as their primary therapy.
• APR discontinuation occurred in 6 patients; reasons for discontinuation included loss of effi cacy (n=2), poor tolerability (n=3), and noncompliance (n=2); 1 patient discontinued due to both poor tolerability and noncompliance. Table 1 .
• Patients given APR had been treated by the responding dermatologists for a mean of 24.8 months, with offi ce visits occurring at a mean of every 2.8 months. 
Clinical Effectiveness of APR Treatment for Moderate Psoriasis • In patients receiving APR as their primary therapy, mean BSA changed from 9.9% at initial chart review to 4.9% at the 6-month chart review ( Figure 5 ). • Of patients receiving APR as their primary therapy, 54% were rated as having mild psoriasis at the 6-month chart review, marking a shift for these patients from moderate psoriasis at baseline ( Figure 6 ). • At the 6-month chart review, 65% of patients receiving APR as primary therapy were rated by dermatologists as having shown at least some improvement; 17% were rated as having shown signifi cant improvement (Figure 7) .
• When asked about their clinical experience with APR, 68% of dermatologists stated that APR exceeded or met their expectations. 
Side Effects With APR Reported During the 6-Month Chart Review Period
• Among patients with available safety information, 8/66 (12%) reported side effects during treatment; these included diarrhea (n=5), nausea (n=3), abdominal pain (n=3), and headache (n=1).
-All side effects were considered mild, except 1 case of diarrhea that was considered moderate; 2 patients took loperamide to manage diarrhea.
• On average, side effects resolved within 2 weeks, with the exception of abdominal pain, which persisted for an average of 7 weeks.
• 1 patient temporarily discontinued APR because of diarrhea but was re-initiated and continued on treatment.
CONCLUSIONS CONCLUSIONS
• In the real-world clinical setting, widely varying BSA cutoff values to identify moderate psoriasis reveal a lack of consensus surrounding the defi nition of moderate psoriasis among US dermatologists.
• Based on patient chart review, APR is well tolerated and effective for treatment of moderate psoriasis.
